Cancers, including those incurable ones, can be treated with a bispecific antibody by allowing T cells to attack the treatment-resistant cancers, scientists claimed. According to Medical Express, since there are too many tumors that do not respond to immunotherapy, it remains an imperfect medical tool.
Some photos of our work in the chemistry lab! We achieved to get a clean product
we synthesised the linker, which is a pre-stage for our bispecific antibody#lab #wetlab #results #labour #chemistry #igem #igem2019 #biology #syntheticbiology #science #erlangen #germany #fau pic.twitter.com/d7fqmynUr7 — iGEM Erlangen 2019 (@iGEM_Erlangen) June 30, 2019
This problem might be solved by an evolving class of engineered proteins called "bispecific' antibodies. This antibody is named after the dual recognition capability and can bind to the surface antigen of a cancer cell itself. It is also engineered to home in on a T cell surface receptor. The results of the study were published in Science Mag.
Its main goal is to activate T cell's tumor annihilating capability and bring two types of cells together. The Regeneron Pharmaceuticals, a leading biotechnology company, located in Tarrytown, New York, is currently studying the bispecific antibodies.
The company's REGN-EB3, a triple antibody cocktail, outperformed other experimental treatment last year for Ebola, because of its promising development. It is currently being reviewed by the United States Food and Drug Administration (FDA), expecting it to receive full approval this year. Regeneron scientists are currently studying an antibody-based treatment for the novel coronavirus.
How bispecific antibodies work
The report also confirmed that Regeneron's bispecific antibodies have grown out of a sobering reality since there are some cancers that developed deceptive strategies that give them the ability to resist immunotherapy. To overcome cancer's evolution, the investigational bispecific antibodies were designed to overcome cancer-cell resistance.
Results of Phase I trial of JNJ-31186372 EGFR-cMet bispecific antibody show preliminary significant clinical efficacy. Patients experiencing post-osimertinib resistance currently being enrolled! @EGFRResisters #WCLC2018 #lcsm #lungcancer pic.twitter.com/XLTBr70XDB — Ivy Elkins (@ivybelkins) September 25, 2018
Dimitris Skokos and Janelle Waite, the scientists who are part of a large Regeneron team, made advancement in testing a class of co-stimulatory CD28-bispecific antibodies. Since the checkpoint blockade immunotherapy relies on drugs known as immune checkpoint inhibitors, it is already considered as an innovative form of cancer therapy.The scientists designed it to engage the body's T cells to treat multiple forms of cancer, by recognizing and attacking malignant cells.
This article is owned by TechTimes,
Written by: Giuliano de Leon.